Support For Continued EU Co-operation On Health Technology Assessment Is ‘Overwhelming’
Executive Summary
Support is strong for continuing EU co-ordination on health technology assessment, according to a report on the responses to a consultation on the topic. An impact assessment on what will follow the EUnetHTA Joint Action 3 will come in late 2017.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.